Roth/MKM Starts OS Therapies, Inc (OSTX) at Buy, PT $7, 'Durable Survival Supports OST-HER2 Approval'

Roth/MKM analyst Adam Walsh initiates coverage on OS Therapies, Inc (NYSE: OSTX) with a Buy rating and a price target of $7.00.

The analyst comments "Initiating Buy, $7 target. We believe OST-HER2 works and approval is more a question of timing. The Listeria immunotherapy achieved 75% 2.5-year overall survival (OS) versus 47% for a pooled historical control (p=0.003) in recurrent, fully resected, pulmonary metastatic osteosarcoma. Milestones are FDA alignment on the endpoint and comparator, and the three-year OS update in early fall 2026. We expect US accelerated approval (70% POA) in late 4Q26 followed by issuance and sale of a Priority Review Voucher (PRV) for $180 million in 1Q27, which would exceed OSTX's current market capitalization and fund cash-flow positivity."

For an analyst ratings summary and ratings history on OS Therapies, Inc click here. For more ratings news on OS Therapies, Inc click here.

Shares of OS Therapies, Inc closed at $1.46 yesterday.

You May Also Be Interested In

• Bumble Inc. (BMBL) PT Lowered to $3.20 at Citi
• DeFi Technologies posts $7.8M revenue and $2.3M loss in Q2 2026
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c